These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16525565)

  • 21. Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products.
    McCulloch P; Nieuwenhuizen W; Douglas J; Lowe GD; George WD
    Haemostasis; 1990; 20(2):73-80. PubMed ID: 2189796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The rational use of coagulation studies in obstetrics: an audit.
    Basu SN; Constantine G; Bareford D
    Br J Obstet Gynaecol; 1990 May; 97(5):452-4. PubMed ID: 2372531
    [No Abstract]   [Full Text] [Related]  

  • 23. Performance of quantitative D-dimer methods: results of the Italian external quality assessment scheme.
    Tripodi A; Chantarangkul V
    J Thromb Haemost; 2007 Jan; 5(1):184-5. PubMed ID: 17026646
    [No Abstract]   [Full Text] [Related]  

  • 24. D-dimer and fibrinogen/fibrin degradation products.
    Stang LJ
    Methods Mol Biol; 2013; 992():415-27. PubMed ID: 23546734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordant D-dimer results of two rapid quantitative automated assays are related to age.
    Barro C; Bosson JL; Satger B; Polack B; Pernod G
    J Thromb Haemost; 2008 Nov; 6(11):1970-1. PubMed ID: 18761724
    [No Abstract]   [Full Text] [Related]  

  • 26. Tanned red cell haemagglutination-inhibition immunoassay of fibrinogen-fibrin degradation products.
    Kings GL; Stoodley KD
    Med Lab Sci; 1980 Oct; 37(4):317-22. PubMed ID: 7207041
    [No Abstract]   [Full Text] [Related]  

  • 27. Colorimetric detection of D-dimer in a paper-based immunodetection device.
    Ruivo S; Azevedo AM; Prazeres DMF
    Anal Biochem; 2017 Dec; 538():5-12. PubMed ID: 28923311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Blood coagulation tests ].
    Fukue H; Fukutake K
    Rinsho Byori; 1997 Nov; Suppl():99-106. PubMed ID: 9508613
    [No Abstract]   [Full Text] [Related]  

  • 29. Altered blood coagulation in patients with posttraumatic stress disorder.
    von Känel R; Hepp U; Buddeberg C; Keel M; Mica L; Aschbacher K; Schnyder U
    Psychosom Med; 2006; 68(4):598-604. PubMed ID: 16868270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Familial dysfibrinogenemia with abnormal nonomer aggregation. Paris III fibrinogen].
    Soria J; Soria C
    Pathol Biol (Paris); 1974 Nov; 22 suppl():72-9. PubMed ID: 4620099
    [No Abstract]   [Full Text] [Related]  

  • 31. Coagulation biomarkers in critically ill patients.
    Levi M; Schultz M; van der Poll T
    Crit Care Clin; 2011 Apr; 27(2):281-97. PubMed ID: 21440202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis of the prethrombotic state in clinical practice].
    Makatsariia AD; Mishchenko AL
    Sov Med; 1982; (6):56-60. PubMed ID: 6750807
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical significance of D Dimer analysis in blood coagulation and fibrinolysis tests].
    Kurokawa I; Kondo H
    Nihon Rinsho; 1989 Dec; 48 Suppl():901-5. PubMed ID: 2695675
    [No Abstract]   [Full Text] [Related]  

  • 34. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
    Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
    Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of freezing plasma at -20°C for 2 weeks on prothrombin time, activated partial thromboplastin time, dilute Russell viper venom time, activated protein C resistance, and D-dimer levels.
    Foshat M; Bates S; Russo W; Huerta A; Albright K; Giddings K; Indrikovs A; Qian YW
    Clin Appl Thromb Hemost; 2015 Jan; 21(1):41-7. PubMed ID: 24842886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proceedings: Quantitative determination of fibrinogen-fibrin degradation products by viro-immunoassay.
    Lederman S; Rimon A
    Isr J Med Sci; 1975 Dec; 11(12):1395. PubMed ID: 1218992
    [No Abstract]   [Full Text] [Related]  

  • 37. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.
    Matsuda M; Baba M; Morimoto K; Nakamikawa C
    J Clin Invest; 1983 Sep; 72(3):1034-41. PubMed ID: 6886002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytical performance of the new ACL AcuStar HemosIL D-Dimer.
    Lippi G; Ippolito L; Russello T; Ponzo V; Salvagno GL; Guidi GC
    Blood Coagul Fibrinolysis; 2012 Mar; 23(2):164-7. PubMed ID: 22227957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparability of D-dimer assays in clinical samples.
    Freyburger G; Labrouche S
    Semin Vasc Med; 2005 Nov; 5(4):328-39. PubMed ID: 16302154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis.
    Morse M
    J Thromb Haemost; 2004 Jul; 2(7):1202-4. PubMed ID: 15219216
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.